Drug Trial Radar · NCT03097861
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
Last checked: Nov 19, 2026Latest source record: Jan 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Mar 13, 2017
Primary completion
Aug 17, 2017
Study completion Aug 17, 2017
Sponsor
- Lead sponsor
- Sucampo Pharma Americas, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Sucampo AG; Sucampo Pharmaceuticals, Inc.
- First posted
- Mar 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
Conditions
- Chronic Idiopathic Constipation
Interventions
LubiprostoneDrug
24 mcg administered orally BID
PlaceboDrug
24 mcg administered orally BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed Spontaneous Bowel Movement (SBM) Count Within 1 WeekTime frame: during the 1-week treatment period
Locations
67 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Birmingham, Alabama
Investigative Site
Foley, Alabama
Investigative Site
Little Rock, Arkansas
Investigative Site
Anaheim, California
Investigative Sitee
Chula Vista, California
Investigative Site
Garden Grove, California
Investigative Site
Long Beach, California
Investigative Site
Los Angeles, California
Investigative Site
Panorama City, California
Investigative Site
San Diego, California
Investigative Site
San Marcos, California
Investigative Site
Upland, California
Investigative Site
Colorado Springs, Colorado
Investigative Site
New London, Connecticut
Investigative Site
Clearwater, Florida
Investigative Site
Coral Springs, Florida
Investigative Site
DeLand, Florida
Investigative Site
Hialeah, Florida
Investigative Site
Jupiter, Florida
Investigative Site
Miami, Florida
Investigative Site 2
Miami, Florida
Investigative Site
Miami, Florida
Investigative Site
Miami, Florida
Investigative Site
Orlando, Florida
Investigative Site
Plantation, Florida
Investigative Sitee
Port Orange, Florida
Investigative Site
Port Saint Lucie, Florida
Investigative Site
Tampa, Florida
Investigative Site
Tampa, Florida
Investigative Site
West Palm Beach, Florida
Investigative Site
Athens, Georgia
Investigative Site
Snellville, Georgia
Investigative Site
Stockbridge, Georgia
Investigative Site
Blackfoot, Idaho
Investigative Site
Boise, Idaho
Investigative Site
Meridian, Idaho
Investigative Site
Lake Charles, Louisiana
Investigative Site
New Orleans, Louisiana
Investigative Site
Shreveport, Louisiana
Investigative Site
Chevy Chase, Maryland
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.